Financial Fitness Check: Examining Esperion Therapeutics Inc. (ESPR)’s Key Ratios

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Esperion Therapeutics Inc. (NASDAQ: ESPR) closed at $2.21 down -3.49% from its previous closing price of $2.29. In other words, the price has decreased by -$3.49 from its previous closing price. On the day, 8.66 million shares were traded. ESPR stock price reached its highest trading level at $2.34 during the session, while it also had its lowest trading level at $2.18.

Ratios:

For a deeper understanding of Esperion Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 2.22.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 18 ’24 when Foody Joanne M. sold 3,285 shares for $2.87 per share. The transaction valued at 9,418 led to the insider holds 273,779 shares of the business.

Warren Eric sold 2,540 shares of ESPR for $7,254 on Jun 18 ’24. The Chief Commercial Officer now owns 165,586 shares after completing the transaction at $2.86 per share. On May 17 ’24, another insider, Warren Eric, who serves as the Chief Commercial Officer of the company, sold 192 shares for $2.48 each. As a result, the insider received 477 and left with 168,126 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 418706592 and an Enterprise Value of 740969216. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.64. Its current Enterprise Value per Revenue stands at 3.225 whereas that against EBITDA is -21.437.

Stock Price History:

Over the past 52 weeks, ESPR has reached a high of $3.40, while it has fallen to a 52-week low of $0.70. The 50-Day Moving Average of the stock is -3.11%, while the 200-Day Moving Average is calculated to be 13.88%.

Shares Statistics:

For the past three months, ESPR has traded an average of 8.48M shares per day and 9571040 over the past ten days. A total of 170.42M shares are outstanding, with a floating share count of 154.69M. Insiders hold about 9.23% of the company’s shares, while institutions hold 71.03% stake in the company. Shares short for ESPR as of 1715731200 were 24911275 with a Short Ratio of 2.58, compared to 1713139200 on 18601646. Therefore, it implies a Short% of Shares Outstanding of 24911275 and a Short% of Float of 13.18.

Earnings Estimates

Esperion Therapeutics Inc. (ESPR) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.18 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.25, while EPS last year was -$0.46. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.03 and low estimates of -$0.2.

Analysts are recommending an EPS of between $0.17 and -$0.26 for the fiscal current year, implying an average EPS of -$0.04. EPS for the following year is $0.0, with 4.0 analysts recommending between $0.63 and -$0.32.

Revenue Estimates

A total of 7 analysts believe the company’s revenue will be $47.04M this quarter.It ranges from a high estimate of $60M to a low estimate of $37.8M. As of the current estimate, Esperion Therapeutics Inc.’s year-ago sales were $25.79MFor the next quarter, 7 analysts are estimating revenue of $66.19M. There is a high estimate of $83.4M for the next quarter, whereas the lowest estimate is $49M.

A total of 7 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $384.5M, while the lowest revenue estimate was $292.8M, resulting in an average revenue estimate of $324.92M. In the same quarter a year ago, actual revenue was $116.33MBased on 5 analysts’ estimates, the company’s revenue will be $416.86M in the next fiscal year. The high estimate is $664.8M and the low estimate is $291.8M.

Most Popular